GlassScriptPhysician profile
Marvin S Moul
NPI 1811180664
$375.45
in general payments reported to CMS, 2019-2025
11 companies · $22.73 in 2025
The $22.73 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $20.82 · 2021: $35.21 · 2022: $24.61 · 2025: $22.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $87.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $52.58 | 2019-2021 | |
| Abbott Laboratories | $47.34 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $41.90 | 2019 | |
| Amgen INC. | $29.79 | 2019 | |
| Novo Nordisk INC | $29.18 | 2019 | |
| Astellas Pharma US INC | $26.59 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.85 | 2019 | |
| Merck Sharp & Dohme LLC | $13.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Moul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.